Therapy and Antifungal Susceptibility Profile of Microsporum canis

Area of Science:

• Veterinary Mycology
• Dermatophytosis Research
• Antifungal Drug Discovery

Background:

• Microsporum canis is a globally prevalent zoophilic dermatophyte causing alopecia and skin lesions in animals and humans.
• Current antifungal treatments for M. canis infections show variable efficacy, with treatment failures reported in up to 40% of cases, potentially due to resistance.
• A significant challenge in managing unresponsive cases is the absence of standardized methods for assessing M. canis antifungal susceptibility.

Purpose of the Study:

• To summarize current data on conventional therapies for Microsporum canis infections.
• To review protocols used for testing the antifungal activity of common drugs against M. canis.
• To analyze the impact of technical parameters in antifungal susceptibility testing on minimum inhibitory concentration (MIC) values and clinical outcomes.

Main Methods:

• Literature review of conventional therapies for M. canis.
• Analysis of published protocols for antifungal susceptibility testing (AST) of M. canis.
• Evaluation of factors influencing minimum inhibitory concentration (MIC) determination in AST.

Main Results:

• Conventional antifungal drugs include azoles, polyenes, allylamines, and griseofulvin.
• Antifungal susceptibility testing methods vary, impacting reported minimum inhibitory concentration (MIC) values.
• Standardization of AST methods is crucial for accurate resistance assessment.

Conclusions:

• Standardized antifungal susceptibility testing methods are essential for Microsporum canis to guide effective treatment strategies.
• Understanding the influence of technical parameters on MIC values is critical for interpreting resistance data.
• Improved diagnostic approaches are needed to address variable treatment efficacy and potential resistance in M. canis infections.